Last reviewed · How we verify
Somatotropin growth hormone recombinant human
Recombinant human somatotropin (growth hormone) binds to growth hormone receptors to stimulate growth, metabolism, and protein synthesis.
Recombinant human somatotropin (growth hormone) binds to growth hormone receptors to stimulate growth, metabolism, and protein synthesis. Used for Growth hormone deficiency in children, Growth hormone deficiency in adults, Short stature due to growth hormone insufficiency.
At a glance
| Generic name | Somatotropin growth hormone recombinant human |
|---|---|
| Sponsor | Rabin Medical Center |
| Drug class | Growth hormone (recombinant) |
| Target | Growth hormone receptor (GHR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Somatotropin is a recombinant form of human growth hormone (GH) that activates GH receptors on target tissues, promoting linear growth in children, increasing muscle mass, reducing fat mass, and enhancing metabolic function. It stimulates insulin-like growth factor 1 (IGF-1) production, which mediates many of its anabolic and growth-promoting effects.
Approved indications
- Growth hormone deficiency in children
- Growth hormone deficiency in adults
- Short stature due to growth hormone insufficiency
Common side effects
- Injection site reactions
- Headache
- Hyperglycemia
- Arthralgia
- Carpal tunnel syndrome
- Fluid retention
Key clinical trials
- Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) (PHASE4)
- Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR) (PHASE1, PHASE2)
- A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature (PHASE2)
- Growth Hormone Administration and the Human Immune System (PHASE1)
- A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow (PHASE3)
- The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature (PHASE3)
- Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders (PHASE3)
- A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: